WASHINGTON - The collaborative research agreement between Scripps Research Institute and Sandoz Pharmaceuticals Corp. has been transformed from a taxpayer rip-off to a model agreement, according to vocal critics of the original deal on Capital Hill and at NIH.

The new agreement is smaller in scope, gives Sandoz less control over Scripps and its scientists, and features innovative mechanisms for promoting technology transfer to small businesses.